Navigating Medicare Advantage Coverage Challenges: A Case Study

Margaret Hvatum, a resident of suburban St. Louis, recently navigated significant challenges with her Humana Medicare Advantage plan, disrupting her healthcare regimen. Relying on Hizentra for primary immunodeficiency, Hvatum faced a denial of coverage from Humana after switching plans. Without insurance, the medication costs over $8,000 for a 28-day supply, making coverage crucial.

The issue began when Humana denied the prior authorization request, a common insurance requirement for treatment approval. Despite having previous authorization from another insurer, the transition left her without coverage, leading to missed doses. Consequently, Hvatum developed a urinary tract infection, requiring emergency room care and resulting in a hospital stay with costs exceeding $18,000, which Humana initially denied.

Understanding Prior Authorization Delays

The prior authorization process is prevalent in Medicare Advantage plans, intended to manage costs by funding only necessary care. While this is economically beneficial for insurers, it may delay patient care, as noted by experts like Carrie Graham from Georgetown University. Insurers profit when care costs less than the government allowances for each member.

In 2024, Medicare Advantage plans reviewed over 53 million authorization requests. Although appeals frequently reverse initial denials, as in Hvatum's case, they can be cumbersome. Hvatum eventually succeeded with her appeal, prompting Humana to reverse its decision on her medication, albeit temporarily.

Insurers' Pledge to Ease Authorization Burdens

Following public criticism, significant insurers, including Humana, have vowed to lessen prior authorization requirements but with certain constraints. Humana’s commitment pertains to medical services and excludes prescription medications. This limited scope suggests that patients like Hvatum may continue to face hurdles in accessing necessary treatments.

Hvatum's challenges extended to another hospital denial during a stroke hospitalization, initially deemed insufficiently serious by Humana. An appeal led to the reversal of this decision as well. Her experiences highlight the critical role of appeals in obtaining coverage and underscore industry discussions about balancing cost control with patient access within Medicare Advantage plans.